Investigator Studies Program (MISP): Antimicrobial Stewardship
Effective January 2022, the Antimicrobial Stewardship Investigator Studies Program (MISP) Committee will accept protocols within our current areas of interest (AOI) up to June 15, 2022. This is a competitive process that will be conducted by the Antimicrobial Stewardship MISP in 2022. Decisions will be made based on scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

The following areas are of interest to Investigator Studies Program Committee:

The Antimicrobial Stewardship MISP proposals should have an intervention with a measurable outcome or outcomes and not be descriptive or observational only. Thought should be given to the scalability of the study or intervention to other settings; higher priority will be given to those studies in which the intervention can be scaled to other centers and demonstrate sustainability beyond the lifetime of the funded study. For those proposals describing the integration of ASPs and/or instituting specific interventions to improve stewardship principles across an integrated delivery network or system, a thorough description of the network and existing challenges and program landscape would be appreciated.

  • Studies that evaluate and assess the impact of ASP interventions aimed at reducing/eliminating demonstrated health disparities related to antimicrobial resistance and/or appropriate antimicrobial use that include both health equity and patient level outcomes.
  • Evaluation of the impact of ASP intervention(s) on outcomes that may include, but are not limited to, the following. Preference will be given to studies that stratify outcomes by REGAL and/or social determinants of health (SDoH) factors (REGAL = race, ethnicity, gender (SOGI – sexual orientation, gender identity), age, language preference
    • Novel metrics for ASPs and/or development/validation/demonstration of surrogate measures (e.g., do process measures like appropriate therapy, guideline adherence, etc. actually correlate to improved patient outcomes?)
    • Assessment of specific AMR trends over time in an institution, healthcare system or patient and the impact of an ASP intervention including implementation of any tools assessing health equity on those trends

  • Evaluation of the most effective strategies for antimicrobial stewardship, including surveillance, infection prevention, streamlining of antibiotic therapy in alternative settings, transitions of care, special/vulnerable populations, and/or resource limited settings
  • Integration of ASPs across integrated delivery networks (IDNs), or accountable care organizations (ACOs)
  • Development and integration of ASP practices in regions with unmet need in the US; this may include the utilization of telemedicine/telehealth to deploy and to measure the intervention.
  • Effect of the COVID-19 pandemic on the conduct, modification, or impact of inpatient or outpatient ASPs.
  • Studies demonstrating the effect of vaccines on AMR trends as potential AMS intervention to decrease antibiotic utilization.
  • Studies which integrate a One Health approach to AMS

Please complete a protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US).The protocols will be collectively reviewed and selected by the Antimicrobial Stewardship MISP Committee.

Critical Activities and Timelines:
Activity Review Cycle
Protocol Submission with Detailed Budget Deadline June 15, 2022
MISP-RC Review Meeting July 13, 2022


MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.